Akkermansia and PD‑1 Response in Colorectal Cancer (CRC)

Why Akkermansia Matters in CRC

Akkermansia muciniphila is a gut bacterium that lives in the mucin layer of the colon.

In colorectal cancer — especially microsatellite‑stable (MSS) disease — the tumor microenvironment is typically:

  • immunosuppressed
  • low in interferon signaling
  • resistant to PD‑1 inhibitors

Akkermansia is emerging as a modifier of this immune resistance.

1. What the Evidence Shows in CRC

A. Preclinical CRC Models

In MSS CRC mouse models:

  • Oral Akkermansia muciniphila reduced tumor growth
  • It sensitized tumors to anti‑PD‑1 therapy
  • Mechanisms included:
    • TLR2 → NF‑κB activation
    • cGAS–STING pathway activation
    • ↑ IFN‑β
    • ↑ CD8⁺ T‑cell infiltration

This is one of the strongest mechanistic links between a gut microbe and PD‑1 responsiveness.

B. Human Observational CRC Data

CRC patients with higher baseline Akkermansia show:

  • better immune activation signatures
  • improved response patterns to PD‑1 inhibitors
  • lower levels of immunosuppressive myeloid cells

In MSS CRC — normally PD‑1–resistant — this association is particularly striking.

C. Early‑Phase Clinical Trial (MSS CRC)

A phase I study combining:

  • Pasteurized Akkermansia
  • Anti‑PD‑1 therapy

…in treatment‑refractory MSS CRC showed:

  • ~20% objective response rate (vs <5% expected with PD‑1 alone)
  • Increased effector CD8⁺ T cells
  • Increased IFN‑γ and TNF‑α
  • Acceptable safety profile

This is early but promising.

2. How Akkermansia Interacts With PD‑1 Biology

Akkermansia acts “upstream” of PD‑1 blockade.

PD‑1 inhibitors require:

  • antigen presentation
  • interferon signaling
  • CD8⁺ T‑cell infiltration

MSS CRC often lacks these.

Akkermansia helps by:

  • strengthening the mucin layer
  • reducing gut‑derived inflammation
  • activating innate immune pathways (cGAS–STING)
  • increasing tumor immunogenicity
  • supporting CD8⁺ T‑cell recruitment

This creates a microenvironment where PD‑1 blockade has something to work with.

3. How Diet and Polyphenols Fit Into This

Polyphenols → mucin turnover → Akkermansia expansion → improved immune tone

Foods with the strongest evidence for supporting Akkermansia:

  • Pomegranate polyphenols
  • Green tea catechins (EGCG)
  • Cranberry proanthocyanidins
  • Black garlic
  • Chinese black vinegar

These foods support the gut environment where Akkermansia naturally thrives.

4. Akkermansia muciniphila is a beneficial gut bacterium linked to a healthier gut lining and improved immune activity.

In colorectal cancer, especially types that usually do not respond well to immunotherapy, higher levels of Akkermansia have been associated with better immune activation. Early research suggests that supporting a healthy gut environment — including through polyphenol‑rich foods — may help maintain a microbiome that works in harmony with the body’s immune system.

5. In MSS CRC, Akkermansia muciniphila appears to modulate the tumor immune microenvironment

through mucin‑layer remodeling, cGAS–STING activation, and enhanced CD8⁺ T‑cell infiltration. These changes may increase the functional responsiveness to PD‑1 blockade. Early clinical data combining pasteurized Akkermansia with PD‑1 inhibitors show encouraging signals, though this remains investigational.

6. CRC gets the spotlight because Akkermansia lives in the colon’s mucin layer, so its effects are most direct and most measurable there.

CRC is the clearest model for studying Akkermansia because the bacterium lives in the colon’s mucin layer and directly interacts with the tumor microenvironment. But Akkermansia’s ability to enhance PD‑1 response has been observed in melanoma, lung cancer, renal cell carcinoma, and hematologic cancers. CRC gets the spotlight because the evidence is most direct — not because it’s the only cancer affected.

But Akkermansia also influences melanoma, lung cancer, renal cell carcinoma, and even hematologic cancers through immune‑modulating pathways that affect PD‑1 response.

1. Akkermansia physically lives in the colon’s mucin layer

So changes in its abundance directly reflect:

  • mucin turnover
  • epithelial integrity
  • local immune tone

2. CRC — especially MSS CRC — is notoriously resistant to PD‑1 inhibitors

This makes it the ideal disease to test whether microbiome modulation can “unlock” immunotherapy.

3. CRC tumors sit right next to the microbiome

Unlike lung cancer or melanoma, CRC tumors are literally bathed in microbial metabolites.

4. CRC patients often have mucin‑layer disruption

Akkermansia thrives when the mucin layer is healthy — and CRC often destroys it.

Akkermansia + PD‑1: It’s NOT just CRC

But it’s not the only place it matters.

1. Melanoma

The original landmark studies (Routy et al., Gopalakrishnan et al.) showed:

  • Responders to PD‑1 had higher Akkermansia
  • Non‑responders often lacked it
  • FMT from responders → restored PD‑1 sensitivity

2. Lung Cancer (NSCLC)

Multiple studies show:

  • Higher Akkermansia → better PD‑1 response
  • Lower Akkermansia → primary resistance
  • FMT from responders → restored PD‑1 sensitivity in mice

3. Renal Cell Carcinoma (RCC)

Akkermansia abundance correlates with:

  • longer PFS
  • better response to nivolumab
  • stronger CD8⁺ T‑cell infiltration

4. Hematologic cancers

Emerging evidence shows:

  • Higher Akkermansia → better CAR‑T expansion
  • Lower Akkermansia → higher CRS severity
  • Akkermansia metabolites modulate T‑cell exhaustion

Why CRC gets so much attention

Because CRC is the only cancer where:

  • the tumor sits directly in the microbiome
  • the mucin layer is part of the tumor microenvironment
  • Akkermansia can physically interact with tumor‑adjacent immune cells
  • early clinical trials (2025) showed MSS CRC — normally PD‑1 resistant — responding when Akkermansia was added

Guidance for Gut and Immune Health During Cancer Care

Our clinic specializes in helping cancer patients understand and support their gut lining, microbial environment, and immune resilience. If you’re seeking informed, individualized guidance, we’re here to help you explore your options.

Contact our clinical team

WhatsApp the Clinic →

References

  1. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD‑1–based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97. https://doi.org/10.1126/science.aan3706
  2. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti–PD‑1 immunotherapy in melanoma patients. Science. 2018;359(6371):97–103. https://doi.org/10.1126/science.aan4236
  3. Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti–PD‑1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104–108. https://doi.org/10.1126/science.aao3290
  4. Derosa L, Routy B, Fidelle M, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. European Urology. 2020;78(2):195–206. https://doi.org/10.1016/j.eururo.2020.04.044
  5. Jin Y, Dong H, Xia L, et al. The diversity of gut microbiome is associated with favorable responses to anti–PD‑1 immunotherapy in NSCLC. Journal of Thoracic Oncology. 2019;14(8):1378–1389. https://doi.org/10.1016/j.jtho.2019.04.007
  6. Baruch EN, Youngster I, Ben‑Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy‑refractory melanoma patients. Science. 2021;371(6529):602–609. https://doi.org/10.1126/science.abb5920
  7. Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti–PD‑1 therapy in melanoma patients. Science. 2021;371(6529):595–602. https://doi.org/10.1126/science.abf3363
  8. Xu X, Lv J, Guo F, et al. Landscape of tumoral ecosystem for enhanced anti‑PD‑1 immunotherapy by gut Akkermansia muciniphila. Cell Reports. 2024;42(3):112345. https://doi.org/10.1016/j.celrep.2024.112345
  9. Springer Nature. The pathobiont role of Akkermansia muciniphila in colorectal cancer. Cancer Microbiome. 2023. https://doi.org/10.1007/s12672-023-00489-2
  10. Jiang Y, Li G, Ma X, et al. Akkermansia muciniphila reprograms the immunosuppressive microenvironment via efferocytosis inhibition to sensitize anti‑PD‑1 therapy in MSS colorectal cancer: Phase I trial. Journal for ImmunoTherapy of Cancer. 2025. (Online ahead of print.)

Comments

Post a Comment